481 related articles for article (PubMed ID: 19701842)
1. Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?
Schmuecking M; Boltze C; Geyer H; Salz H; Schilling B; Wendt TG; Kloetzer KH; Marx C
Int J Radiat Biol; 2009 Sep; 85(9):814-24. PubMed ID: 19701842
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
3. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.
Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B
J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.
Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B
Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190
[TBL] [Abstract][Full Text] [Related]
5. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
Cirillo S; Petracchini M; Della Monica P; Gallo T; Tartaglia V; Vestita E; Ferrando U; Regge D
Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
[TBL] [Abstract][Full Text] [Related]
6. Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy.
Roy C; Foudi F; Charton J; Jung M; Lang H; Saussine C; Jacqmin D
AJR Am J Roentgenol; 2013 Apr; 200(4):W361-8. PubMed ID: 23521479
[TBL] [Abstract][Full Text] [Related]
7. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.
Martorana G; Schiavina R; Corti B; Farsad M; Salizzoni E; Brunocilla E; Bertaccini A; Manferrari F; Castellucci P; Fanti S; Canini R; Grigioni WF; D'Errico Grigioni A
J Urol; 2006 Sep; 176(3):954-60; discussion 960. PubMed ID: 16890665
[TBL] [Abstract][Full Text] [Related]
8. Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection.
Perdonà S; Di Lorenzo G; Autorino R; Buonerba C; De Sio M; Setola SV; Fusco R; Ronza FM; Caraglia M; Ferro M; Petrillo A
Urol Oncol; 2013 Aug; 31(6):761-5. PubMed ID: 21906966
[TBL] [Abstract][Full Text] [Related]
9. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate.
Kuru TH; Roethke MC; Rieker P; Roth W; Fenchel M; Hohenfellner M; Schlemmer HP; Hadaschik BA
BJU Int; 2013 Dec; 112(8):1080-7. PubMed ID: 23937255
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
Vilanova JC; Barceló-Vidal C; Comet J; Boada M; Barceló J; Ferrer J; Albanell J
AJR Am J Roentgenol; 2011 Jun; 196(6):W715-22. PubMed ID: 21606259
[TBL] [Abstract][Full Text] [Related]
11. A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific antigen levels: prospective comparison with ultrasound-guided transrectal biopsy.
Ferda J; Kastner J; Hora M; Hes O; Fínek J; Topolčan O; Kreuzberg B
Anticancer Res; 2013 Jun; 33(6):2791-5. PubMed ID: 23749943
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
Haider MA; Chung P; Sweet J; Toi A; Jhaveri K; Ménard C; Warde P; Trachtenberg J; Lockwood G; Milosevic M
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):425-30. PubMed ID: 17881141
[TBL] [Abstract][Full Text] [Related]
13. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.
Casciani E; Polettini E; Bertini L; Emiliozzi P; Amini M; Pansadoro V; Gualdi GF
Radiol Med; 2004; 108(5-6):530-41. PubMed ID: 15722999
[TBL] [Abstract][Full Text] [Related]
15. Inter-reader agreement of multi-parametric MR imaging for the detection of prostate cancer: evaluation of a scoring system.
Quentin M; Arsov C; Röhlen S; Klasen J; Antoch G; Albers P; Blondin D
Rofo; 2012 Oct; 184(10):925-9. PubMed ID: 22744328
[TBL] [Abstract][Full Text] [Related]
16. [1H magnetic resonance spectroscopy of the prostate].
Mueller-Lisse UG; Scherr M
Radiologe; 2003 Jun; 43(6):481-8. PubMed ID: 12827263
[TBL] [Abstract][Full Text] [Related]
17. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection.
Reinsberg SA; Payne GS; Riches SF; Ashley S; Brewster JM; Morgan VA; deSouza NM
AJR Am J Roentgenol; 2007 Jan; 188(1):91-8. PubMed ID: 17179350
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
[TBL] [Abstract][Full Text] [Related]
19. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
